阿仑膦酸钠对甲亢患者骨密度的影响

目的探讨阿仑膦酸钠对20~40岁甲亢患者骨密度的影响。方法选择正常健康志愿者30例作为正常对照组(B组)。76例甲亢患者随机分为2组:A1组38例,服抗甲亢药;A2组38例,在服抗甲亢药的基础上加服阿仑膦酸钠5 mg/d。2组共服药12个月。结果 A2组腰椎、股骨颈及大粗隆的骨密度均明显升高(P均<0.05),其中腰椎骨密度治疗前为(0.91±0.09)g/cm2,治疗后12个月为(1.11±0.07)g/cm2,增加率30.6%,明显高于A1组(P<0.05)。12个月治疗总有效率A2组为61.2%,显著高于A1组的31.6%(P<0.05)。患者无严重不良反应。结论阿仑膦酸钠能明显提高甲亢患者的骨密度,不良反应少。

Influence of alendronate sodium on bone mineral density in patients with hyperthyroidism

Objective It is to approach the influence of alendronate sodium on bone mineral density in patients with hyperthyroidism whose ages were from 20 to 40 years old.Methods 30 healthy volunteers were chosen as normal control group.76 patients with hyperthyroidism were randomly divided into two groups.38 cases were in group A1 and treated with drugs which were treated for hyperthyroidism,and the other 38 cases were in group A2 and treated with alendronate sodium 5 mg/d on the base of the treatment of group A1.Both the two groups were treated for twelve months.Results Bone mineral density of lumbar vertebra,femoral neck,and greater trochanter in group A2 increased obviously(P<0.05).Among the total,bone mineral density of lumbar vertebra before treatment was(0.91±0.09)g/cm2 and that after treatment for 12 months was(1.11±0.07)g/cm2,and the increased rate was 30.6%,which was obviously higher than that in group A1(P<0.05).No severe untoward reaction was observed in both the two groups.Conclusion Alendronate can obviously heighten the bone mineral density of the patients with hyperthyroidism without severe untoward reaction.